These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1133 related items for PubMed ID: 19031663

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
    Mello MM, Studdert DM, Brennan TA.
    N Engl J Med; 2009 Apr 09; 360(15):1557-66. PubMed ID: 19357413
    [No Abstract] [Full Text] [Related]

  • 5. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM.
    Seton Hall Law Rev; 2011 Apr 09; 41(2):559-92. PubMed ID: 21739759
    [No Abstract] [Full Text] [Related]

  • 6. The ongoing regulation of generic drugs.
    Frank RG.
    N Engl J Med; 2007 Nov 15; 357(20):1993-6. PubMed ID: 18003956
    [No Abstract] [Full Text] [Related]

  • 7. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M.
    N Engl J Med; 2007 Apr 26; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Access before approval--a right to take experimental drugs?
    Okie S.
    N Engl J Med; 2006 Aug 03; 355(5):437-40. PubMed ID: 16885545
    [No Abstract] [Full Text] [Related]

  • 10. Paying for drug approvals--who's using whom?
    Avorn J.
    N Engl J Med; 2007 Apr 26; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract] [Full Text] [Related]

  • 11. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J.
    New Yorker; 2006 Dec 18; ():40-7. PubMed ID: 17176539
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR.
    Suffolk Univ Law Rev; 2003 Dec 18; 36(3):787-819. PubMed ID: 16493844
    [No Abstract] [Full Text] [Related]

  • 16. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Berry MD.
    Issue Brief Health Policy Track Serv; 2012 Dec 31; ():1-79. PubMed ID: 23297449
    [No Abstract] [Full Text] [Related]

  • 17. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL.
    J Natl Cancer Inst; 2005 Jun 15; 97(12):872-3. PubMed ID: 15956645
    [No Abstract] [Full Text] [Related]

  • 18. Remarks at the Food and Drug Law Institute's 48th Annual Conference.
    Niedelman SM.
    Food Drug Law J; 2005 Jun 15; 60(2):117-26. PubMed ID: 16097089
    [No Abstract] [Full Text] [Related]

  • 19. Drug marketing exclusivity under United States and European Union law.
    Junod V.
    Food Drug Law J; 2004 Jun 15; 59(4):479-518. PubMed ID: 15875347
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.